http://purl.org/np/RASkp2LUV6... RASkp2LUV6

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-13T12:49:16.653Z

http://purl.org/np/RASkp2LUV6... RASkp2LUV6

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-13T12:49:16.653528

Elif Ozkan

2022-10-13T12:49:16.653Z

http://purl.org/np/RASkp2LUV6... RASkp2LUV6

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

Vericiguat is indicated in adults with symptomatic, chronic heart failure and an ejection fraction of <45%. It is indicated to reduce the risk of cardiovascular death and heart failure-related hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics. It reduces cardiovascular death, heart failure related hospitalization, and hospitalization associated with heart failure.

Elif Ozkan

2022-10-13T12:49:16.653Z